Newamsterdam Pharma Stock Market Value
| NAMSW Stock | 25.97 0.00 0.00% |
| Symbol | NewAmsterdam |
What growth prospects exist in Biotechnology sector? Can NewAmsterdam capture new markets? Factors like these will boost the valuation of NewAmsterdam Pharma. Anticipated expansion of NewAmsterdam directly elevates investor willingness to pay premium valuations. Valuation analysis balances hard financial data with qualitative growth assessments. While each NewAmsterdam Pharma valuation metric matters, prioritizing which indicators carry greater predictive weight remains essential.
Investors evaluate NewAmsterdam Pharma using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating NewAmsterdam Pharma's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investment professionals apply varied valuation frameworks to compute inherent worth and acquire positions when market prices trade at discounts to calculated value. External factors like market trends, sector rotation, and investor psychology can cause NewAmsterdam Pharma's market price to deviate significantly from intrinsic value.
It's important to distinguish between NewAmsterdam Pharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding NewAmsterdam Pharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, NewAmsterdam Pharma's market price signifies the transaction level at which participants voluntarily complete trades.
NewAmsterdam Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to NewAmsterdam Pharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of NewAmsterdam Pharma.
| 12/02/2025 |
| 03/02/2026 |
If you would invest 0.00 in NewAmsterdam Pharma on December 2, 2025 and sell it all today you would earn a total of 0.00 from holding NewAmsterdam Pharma or generate 0.0% return on investment in NewAmsterdam Pharma over 90 days. NewAmsterdam Pharma is related to or competes with Scholar Rock, Veracyte, Ideaya Biosciences, Kiniksa Pharmaceuticals, Zai Lab, Amicus Therapeutics, and Tarsus Pharmaceuticals. NewAmsterdam Pharma is entity of United States More
NewAmsterdam Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure NewAmsterdam Pharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess NewAmsterdam Pharma upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 32.57 | |||
| Value At Risk | (10.64) | |||
| Potential Upside | 7.05 |
NewAmsterdam Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for NewAmsterdam Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as NewAmsterdam Pharma's standard deviation. In reality, there are many statistical measures that can use NewAmsterdam Pharma historical prices to predict the future NewAmsterdam Pharma's volatility.| Risk Adjusted Performance | 0.0081 | |||
| Jensen Alpha | 0.0668 | |||
| Total Risk Alpha | (0.49) | |||
| Treynor Ratio | 0.0116 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of NewAmsterdam Pharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
NewAmsterdam Pharma March 2, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0081 | |||
| Market Risk Adjusted Performance | 0.0216 | |||
| Mean Deviation | 2.67 | |||
| Coefficient Of Variation | (167,299) | |||
| Standard Deviation | 5.17 | |||
| Variance | 26.71 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | 0.0668 | |||
| Total Risk Alpha | (0.49) | |||
| Treynor Ratio | 0.0116 | |||
| Maximum Drawdown | 32.57 | |||
| Value At Risk | (10.64) | |||
| Potential Upside | 7.05 | |||
| Skewness | (0.42) | |||
| Kurtosis | 4.03 |
NewAmsterdam Pharma Backtested Returns
At this stage we consider NewAmsterdam Stock to be somewhat reliable. NewAmsterdam Pharma has Sharpe Ratio of 0.0108, which conveys that the firm had a 0.0108 % return per unit of risk over the last 3 months. We have found nineteen technical indicators for NewAmsterdam Pharma, which you can use to evaluate the volatility of the firm. Please verify NewAmsterdam Pharma's Mean Deviation of 2.67, risk adjusted performance of 0.0081, and Standard Deviation of 5.17 to check out if the risk estimate we provide is consistent with the expected return of 0.0566%. The company secures a Beta (Market Risk) of -1.13, which conveys a somewhat significant risk relative to the market. As the market becomes more bullish, returns on owning NewAmsterdam Pharma are expected to decrease slowly. On the other hand, during market turmoil, NewAmsterdam Pharma is expected to outperform it slightly. NewAmsterdam Pharma right now secures a risk of 5.25%. Please verify NewAmsterdam Pharma market risk adjusted performance, jensen alpha, as well as the relationship between the Jensen Alpha and rate of daily change , to decide if NewAmsterdam Pharma will be following its current price movements.
Auto-correlation | -0.33 |
Poor reverse predictability
NewAmsterdam Pharma has poor reverse predictability. Overlapping area represents the amount of predictability between NewAmsterdam Pharma time series from 2nd of December 2025 to 16th of January 2026 and 16th of January 2026 to 2nd of March 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of NewAmsterdam Pharma price movement. The serial correlation of -0.33 indicates that nearly 33.0% of current NewAmsterdam Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.33 | |
| Spearman Rank Test | -0.78 | |
| Residual Average | 0.0 | |
| Price Variance | 5.31 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.